Gulf Pharmaceutical Industries P.S.C 過去の業績

過去基準チェック /06

Gulf Pharmaceutical Industries P.S.Cは59%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで10.2%毎年増加している。売上は成長しており、年平均33.3%の割合である。

主要情報

59.0%

収益成長率

70.1%

EPS成長率

Pharmaceuticals 業界の成長	12.4%
収益成長率	33.3%
株主資本利益率	-7.2%
ネット・マージン	-3.5%
前回の決算情報	30 Jun 2024

Recent updates

Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Oct 16

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Jan 15

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Nov 04

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Mar 26

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Feb 08

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Dec 14

収支内訳

Gulf Pharmaceutical Industries P.S.C の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ADX:JULPHAR 収益、費用、利益 ( )AED Millions
日付	収益	収益	G+A経費
30 Jun 24	1,662	-58	602
31 Mar 24	1,623	-98	598
31 Dec 23	1,638	-104	591
30 Sep 23	1,587	-128	609
30 Jun 23	1,637	-85	602
31 Mar 23	1,652	-38	602
31 Dec 22	1,616	-34	596
30 Sep 22	1,651	-28	607
30 Jun 22	1,598	0	604
31 Mar 22	1,398	64	525
31 Dec 21	1,143	47	452
30 Sep 21	858	-104	446
30 Jun 21	682	-138	394
31 Mar 21	632	-203	387
31 Dec 20	573	-247	397
30 Sep 20	540	-184	348
30 Jun 20	376	-377	370
31 Mar 20	295	-472	392
31 Dec 19	302	-494	400
30 Sep 19	265	-957	425
30 Jun 19	388	-840	423
31 Mar 19	567	-716	418
31 Dec 18	720	-612	420
30 Sep 18	928	-20	378
30 Jun 18	1,106	80	385
31 Mar 18	1,085	70	417
31 Dec 17	1,155	95	446
30 Sep 17	1,293	142	640
30 Jun 17	1,275	145	645
31 Mar 17	1,418	178	682
31 Dec 16	1,455	212	703
30 Sep 16	1,391	205	579
30 Jun 16	1,407	215	594
31 Mar 16	1,391	214	646
31 Dec 15	1,470	230	677
30 Sep 15	1,510	226	672
30 Jun 15	1,449	235	663
31 Mar 15	1,443	228	625
31 Dec 14	1,388	204	632
30 Sep 14	1,382	224	630
30 Jun 14	1,427	231	643
31 Mar 14	1,425	238	637
31 Dec 13	1,362	230	597

質の高い収益: JULPHARは現在利益が出ていません。

利益率の向上: JULPHARは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: JULPHARは利益を出していないが、過去 5 年間で年間59%の割合で損失を削減してきた。

成長の加速: JULPHARの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: JULPHARは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 6% ) と比較することは困難です。

株主資本利益率

高いROE: JULPHARは現在利益が出ていないため、自己資本利益率 ( -7.21% ) はマイナスです。

Gulf Pharmaceutical Industries P.S.C 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Second quarter 2024 earnings released

Gulf Pharmaceutical Industries P.S.C. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings released: EPS: د.إ0.002 (vs د.إ0.003 loss in 1Q 2023)

Full year 2023 earnings released: د.إ0.09 loss per share (vs د.إ0.029 loss in FY 2022)

Full year 2023 earnings released: د.إ0.087 loss per share (vs د.إ0.029 loss in FY 2022)

Third quarter 2023 earnings released: د.إ0.034 loss per share (vs د.إ0.003 profit in 3Q 2022)

Recent updates

Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Second quarter 2024 earnings released

Gulf Pharmaceutical Industries P.S.C. to Report Q2, 2024 Results on Aug 14, 2024

Now 21% overvalued

First quarter 2024 earnings released: EPS: د.إ0.002 (vs د.إ0.003 loss in 1Q 2023)

Gulf Pharmaceutical Industries P.S.C., Annual General Meeting, Apr 22, 2024

Full year 2023 earnings released: د.إ0.09 loss per share (vs د.إ0.029 loss in FY 2022)

Full year 2023 earnings released: د.إ0.087 loss per share (vs د.إ0.029 loss in FY 2022)

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Third quarter 2023 earnings released: د.إ0.034 loss per share (vs د.إ0.003 profit in 3Q 2022)

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Second quarter 2023 earnings released: د.إ0.037 loss per share (vs د.إ0.003 profit in 2Q 2022)

First quarter 2023 earnings released

Full year 2022 earnings: EPS and revenues miss analyst expectations

Gulf Pharmaceutical Industries P.S.C. Announces Chief Executive Officer Changes

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: د.إ0.003 (vs د.إ0.028 in 3Q 2021)

Gulf Pharmaceutical Industries P.S.C. to Report Q3, 2022 Results on Nov 09, 2022

Gulf Pharmaceutical Industries P.S.C. Announces Resignation of Sanjay Deshmukh as Chief Operating Officer

Second quarter 2022 earnings released: EPS: د.إ0.003 (vs د.إ0.059 in 2Q 2021)

First quarter 2022 earnings: Revenues miss analyst expectations

Gulf Pharmaceutical Industries P.S.C. to Report Q1, 2022 Results on May 13, 2022

Price target decreased to د.إ1.57

Less than half of directors are independent

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Third quarter 2021 earnings released: EPS د.إ0.028 (vs د.إ0.003 loss in 3Q 2020)

GlobalOne Healthcare acquired Gulf Inject LLC from Gulf Pharmaceutical Industries P.S.C.

Second quarter 2021 earnings released: EPS د.إ0.059 (vs د.إ0.028 loss in 2Q 2020)

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) completed the acquisition of remaining 60% stake in Planet Pharmacies LLC from KAMCO Investment Company K.S.C.P. (KWSE:KAMCO) and others.

An unknown buyer agreed to acquire 51% stake in Alpha Pharma L.L.C. from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR).

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) agreed to acquire a 60% stake in Planet Pharmacies LLC.

First quarter 2021 earnings released: د.إ0.026 loss per share (vs د.إ0.094 loss in 1Q 2020)

Full year 2020 earnings released: د.إ0.28 loss per share (vs د.إ0.75 loss in FY 2019)

New 90-day low: د.إ1.26

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

New 90-day high: د.إ1.55

Radiant Pharmaceuticals Limited acquired Julphar Bangladesh Ltd from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) and RAK Pharmaceuticals Pvt. Ltd. for BDT 1.4 billion.

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

New 90-day high: د.إ1.50

Third quarter 2020 earnings released: د.إ0.015 loss per share

New 90-day high: د.إ1.49

New 90-day high: د.إ1.35

Earnings released

Gulf Pharmaceutical Industries P.S.C. has completed a Follow-on Equity Offering in the amount of AED 500 million.

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06